Simulations Plus, Inc. - Common Stock (NQ:SLP)

18.50 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Simulations Plus, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Simulations Plus Stock Scores Composite Rating Move Up To 96 ↗

July 06, 2022

The IBD SmartSelect Composite Rating for Simulations Plus stock rose from 94 to 96 Wednesday. The medical software stock has 94 RS Rating.

Via Investor's Business Daily

Earnings Scheduled For July 6, 2022 ↗

July 06, 2022

Companies Reporting After The Bell • Saratoga Investment (NYSE:SAR) is expected to report quarterly earnings at $0.53 per share on revenue of $19.21 million.

Via Benzinga

Kornit Digital, Simulations Plus And 3 Stocks To Watch Heading Into Wednesday ↗

July 06, 2022

With the US stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:

Via Benzinga

Preview: Simulations Plus's Earnings ↗

July 05, 2022

Simulations Plus (NASDAQ:SLP) is set to give its latest quarterly earnings report on Wednesday, 2022-07-06. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Simulations Plus Hosts 2nd Annual Pharmacometrics Workshop

June 30, 2022

From Simulations Plus, Inc.

Via Business Wire

Can Simulations Plus Stock Maintain Its Impressive Growth? ↗

April 15, 2022

Simulations Plus, Inc. held up well in the company’s recently released financial results.

Via Talk Markets

Jim Cramer Recommends This Mining Company And 5 Other Stocks ↗

June 29, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said AT&T Inc (NYSE: T) is a "distinct hold. If it were $18, it’s a buy. If it was $23, it’s a sell."

Via Benzinga

Simulations Plus Collaborates with Multinational Pharmaceutical Company to Provide Modeling & Simulation Support for COVID-19 Treatment

June 23, 2022

From Simulations Plus, Inc.

Via Business Wire

Simulations Plus Sets Date for Third Quarter Fiscal Year 2022 Earnings Release and Conference Call

June 21, 2022

From Simulations Plus, Inc.

Via Business Wire

DILIsym Software Publication Outlines Impact on the CGRP Field for Migraine

June 16, 2022

From Simulations Plus, Inc.

Via Business Wire

Privia Health Stock Among The Few That've Risen This Month ↗

June 13, 2022

Privia Health is trying to complete a cup without handle with a 29.07 entry. See if it clears the breakout price in above average volume.

Via Investor's Business Daily

Simulations Plus Releases ADMET Predictor Version 10.4 (X.4)

May 26, 2022

From Simulations Plus, Inc.

Via Business Wire

U.S. FDA Renews Annual DILIsym Software Licenses for 2022

May 05, 2022

From Simulations Plus, Inc.

Via Business Wire

Simulations Plus Successfully Delivers FDA-Funded Project

April 28, 2022

From Simulations Plus, Inc.

Via Business Wire

Simulations Plus Enters New Collaboration to Advance DDDPlus™ Software

April 21, 2022

From Simulations Plus, Inc.

Via Business Wire

Simulations Plus to Present at the Berenberg Discover AI Seminar

April 19, 2022

From Simulations Plus, Inc.

Via Business Wire

Simulations Plus: Q2 Earnings Insights ↗

April 07, 2022

Simulations Plus (NASDAQ:SLP) reported its Q2 earnings results on Wednesday, April 6, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Via Benzinga

Simulations Plus Reports Second Quarter Fiscal 2022 Financial Results

April 06, 2022

From Simulations Plus, Inc.

Via Business Wire

Earnings Preview For Simulations Plus ↗

April 05, 2022

Simulations Plus (NASDAQ:SLP) is set to give its latest quarterly earnings report on Wednesday, 2022-04-06. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Simulations Plus Receives $1.7 Million Grant for BIOLOGXsym™ Macromolecule Safety Software

March 29, 2022

From Simulations Plus, Inc.

Via Business Wire

Simulations Plus Hosts the 2022 Model-Informed Drug Development (MIDD+) Scientific Conference

March 24, 2022

From Simulations Plus, Inc.

Via Business Wire

Simulations Plus Sets Date for Second Quarter Fiscal Year 2022 Earnings Release and Conference Call

March 22, 2022

From Simulations Plus, Inc.

Via Business Wire

Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit National Organization for Rare Disorders

March 17, 2022

From Simulations Plus, Inc.

Via Business Wire

Simulations Plus to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

February 08, 2022

From Simulations Plus, Inc.

Via Business Wire

Simulations Plus Partners with Large Pharmaceutical Company to Drive Advancements to the GastroPlus Mechanistic Oral Absorption Model

January 20, 2022

From Simulations Plus, Inc.

Via Business Wire

Simulations Plus Enters New Collaboration with Leading Animal Health Company

January 13, 2022

From Simulations Plus, Inc.

Via Business Wire

Simulations Plus to Present at Sidoti Winter Small Cap Investor Conference

January 12, 2022

From Simulations Plus, Inc.

Via Business Wire

33 Stocks Moving In Friday's Mid-Day Session ↗

January 07, 2022

Gainers Marin Software Incorporated (NASDAQ: MRIN) shares climbed 35.9% to $4.6899 after the company announced an integration with Amazon Ads' demand-side platform. Absci...

Via Benzinga

56 Biggest Movers From Friday ↗

January 10, 2022

Gainers Hour Loop, Inc. (NASDAQ: HOUR) shares jumped 99.8% to $7.99 after the company priced its IPO at $4 per share. China HGS Real Estate Inc. (NASDAQ: HGSH) shares...

Via Benzinga

Simulations Plus: Q1 Earnings Insights ↗

January 06, 2022

Simulations Plus (NASDAQ:SLP) reported its Q1 earnings results on Thursday, January 6, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.